Quarterly ResultMay 12, 2026, 04:57 PM
Corbus Pharma Q1 Net Loss Widens to $23.0M; R&D Expenses Up 27%
AI Summary
Corbus Pharmaceuticals reported a net loss of $23.0 million for Q1 2026, a significant increase from $17.0 million in Q1 2025, driven by a 27% rise in research and development expenses. The company's cash and investments totaled $138.2 million as of March 31, 2026, which is expected to fund operations for at least twelve months. Subsequent to the quarter, Corbus sold additional common stock for $8.9 million and made a $10.0 million milestone payment for its CRB-701 program.
Key Highlights
- Net loss for Q1 2026 widened to $23.0 million, up 35.3% from $17.0 million in Q1 2025.
- Research and development expenses increased 26.7% to $19.8 million in Q1 2026.
- Net loss per share improved to $(1.23) in Q1 2026 from $(1.39) in Q1 2025.
- Net cash used in operating activities rose to $25.6 million in Q1 2026.
- Cash, cash equivalents, and investments totaled $138.2 million as of March 31, 2026.
- Subsequent to quarter-end, $8.9 million net proceeds were raised from stock sales.
- A $10.0 million development milestone payment was made for CRB-701 in April 2026.
Price Impact
More from CRBP